Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review

Nov 23, 2021Psychopharmacology

Psychedelics for easing depression, anxiety, and distress in terminally ill patients: a systematic review

AI simplified

Psychedelic Science on OpenScience ↗PubMed ↗DOI ↗

Abstract

A total of 33 studies on psychedelic treatment for terminally ill patients indicate promising effects on well-being and mental health.

Classical psychedelics (DPT, LSD, psilocybin) and atypical psychedelics (MDMA, ketamine) were reviewed for treating existential distress, depression, and anxiety.
Early pre-post studies showed promising results but had significant methodological flaws.
Controlled trials demonstrated positive effects on existential and spiritual well-being, quality of life, and reductions in anxiety and depression.
Psychedelic treatments were associated with few adverse effects and no serious adverse effects.
Further research is needed, particularly larger high-quality studies for classical psychedelics and MDMA, to establish effectiveness and safety.

AI simplified

BACKGROUND: Terminally ill patients may experience existential distress, depression, or anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or pharmacological interventions have (time) limited efficacy. Psychedelic treatment may be a safe and effective alternative treatment option.

AIM: Systematically review studies on psychedelic treatment with and without psychotherapy for existential distress, depression, and anxiety in terminally ill patients.

METHODS: Medline, PsycINFO, and Embase were searched for original-data studies on the treatment of depression, anxiety, and existential distress with classical or a-typical psychedelics in patients with a terminal illness, using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

RESULTS: A total of 1850 records were screened, and 33 articles were included in this review: 14 studies on classical psychedelics (DPT, LSD, and psilocybin) and 19 studies on atypical psychedelics (MDMA and ketamine). Results of early pre-post studies are promising but have serious methodological flaws. Recent (controlled) trials with LSD, psilocybin, ketamine, and MDMA are of higher methodological quality and indicate positive effects on existential and spiritual well-being, quality of life, acceptance, and reduction of anxiety and depression with few adverse and no serious adverse effects.

CONCLUSIONS: Both classical and a-typical psychedelics are promising treatment options in patients with terminal illness. To draw final conclusions on effectiveness and safety of psychedelics, we need larger high-quality studies for classical psychedelics and MDMA. Ketamine studies should pay more attention to existential dimensions of well-being and the psychotherapeutic context of the treatment.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief